Biomarin Pharmaceutical Inc
Change company Symbol lookup
Select an option...
BMRN Biomarin Pharmaceutical Inc
BLTS Bright Lights Acquisition Corp
MMM 3M Co
STRR Star Equity Holdings Inc
BMY Bristol-Myers Squibb Co
BCTX Briacell Therapeutics Corp
ENV Envestnet Inc
CDR-B Cedar Realty Trust Inc
EVIO EVIO Inc
WCC Wesco International Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.

Closing Price
$80.97
Day's Change
2.11 (2.68%)
Bid
--
Ask
--
B/A Size
--
Day's High
81.20
Day's Low
78.65
Volume
(Light)
Volume:
659,473

10-day average volume:
952,848
659,473

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.

Valuation Ratios

Price/Earnings (TTM)
513.18x
Price/Sales (TTM)
7.76x
Price/Book (MRQ)
3.32x
Price/Cash Flow (TTM)
102.15x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

May 2022
Current Month
12.2M
Previous Month
11.4M
Percent of Float
6.61%
Days to Cover
8.9900 Days

Share Information

BMRN is in a share class of common stock
Float
182.8M
Shares Outstanding
185.0M
Institutions Holding Shares
811
96.65%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Jean-Jacques BienaimeChmn.
  • Brian R. MuellerCFO
  • Henry J. FuchsCorp.Exec.
  • C. Greg GuyerExec.VP
  • G. Eric DavisExec.VP

Address

Insider Trading

During the most recent quarter, 100 shares were bought, and 203K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.